Celularity Inc. Enters Strategic Commercialization Partnership To Monetize Placental-Derived Biomaterials Portfolio

Celularity Inc., a regenerative and cellular medicine company focused on longevity science, announced that it has entered into definitive agreements establishing a strategic commercialization partnership for its placental-derived biomaterials portfolio. The transaction, expected to close no later than April 15, 2026, is subject to customary closing conditions. This partnership is designed to monetize Celularity’s commercial biomaterials assets while allowing the company to focus its resources on advancing its longevity-focused therapeutic pipeline.

Under the terms of the agreements, Celularity has granted an exclusive license to its commercial-stage biomaterials portfolio as well as certain development-stage programs. The company expects to receive upfront consideration at closing and may receive additional milestone-based payments totaling up to $35 million, providing non-dilutive capital. In addition, Celularity will be eligible to receive royalties on future net sales of selected development-stage products once they are commercialized. 

The company will also serve as the exclusive manufacturer of the licensed products at its FDA-compliant facility in Florham Park, New Jersey, generating a continuing manufacturing revenue stream while maintaining participation in the economic benefits of the licensed products. Celularity’s vertically integrated manufacturing infrastructure is designed to support scalable, quality-driven production for both commercial products and next-generation placental-derived cellular therapeutics.

Robert J. Hariri, M.D., Ph.D., Chairman and Chief Executive Officer of Celularity, said that the partnership represents a disciplined step forward in strengthening the company’s capital position while sharpening its focus on longevity medicine. He highlighted that the company’s proprietary newborn placental cellular technology offers significant biological advantages across a broad set of applications. 

Dr. Hariri noted that the transaction allows Celularity to monetize its commercial infrastructure in a capital-efficient way, reduce operating complexity, and retain long-term economic participation through manufacturing and royalties, while concentrating resources on high-value cellular therapeutics targeting the fundamental mechanisms of aging. pH Partners, LLC served as financial advisor to Celularity in connection with the transaction.

As part of the agreement, personnel associated with the company’s commercial and product development biomaterials activities are expected to transition to the commercial partner at closing. Celularity will further streamline its workforce in line with this organizational realignment, which is intended to lower operating expenses and focus resources on the company’s core longevity-focused therapeutic pipeline and scalable manufacturing platform. This realignment is expected to improve capital efficiency by concentrating investment on high-value clinical and manufacturing initiatives while reducing non-core operating expenditures.

Following the transaction, Celularity will intensify its focus on longevity, developing placental-derived cell therapies aimed at addressing key biological drivers of aging, including cellular senescence, chronic inflammation, and tissue degeneration. The company also plans to expand its commercial and clinical presence in jurisdictions that allow investigational use of cellular and biologic technologies under applicable state frameworks, including Florida, Texas, and Arizona, in compliance with regulatory requirements.

Dr. Hariri added that longevity medicine represents a significant long-term opportunity for Celularity. He noted that emerging investigational pathways may enable physicians and researchers to responsibly evaluate innovative biologic technologies and explore the regenerative potential of placental-derived cell therapies, while the company continues to advance its regulated development programs.